---
title: "Lifecore Biomedical faces $52.1M Series A preferred redemption due Dec. 28, 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291592245.md"
description: "Lifecore Biomedical announced that holders have submitted notices to redeem all 49,263 shares of its Series A preferred stock. This creates a redemption obligation of approximately $52.1 million due on December 28, 2026. The company, which had $38.1 million in liquidity as of March 31, 2026, is evaluating cash, financing, or strategic alternatives and seeking lender consents to facilitate the payment."
datetime: "2026-07-02T21:23:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291592245.md)
  - [en](https://longbridge.com/en/news/291592245.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291592245.md)
---

# Lifecore Biomedical faces $52.1M Series A preferred redemption due Dec. 28, 2026

**Lifecore Biomedical announced holders submitted notices to redeem all 49,263 shares of its Series A preferred, creating a roughly $52.1 million redemption obligation due December 28, 2026.**

**Key Highlights:**

-   Holders submitted redemption notices for all 49,263 outstanding Series A preferred shares on June 29–30, 2026.
-   Redemption price is $1,000 per share plus accrued dividends; total liquidation value ~ $50.2M and accrued dividends $0.9M.
-   Total required payout on Dec. 28, 2026 (180 days) is ~ $52.1M; unpaid balances accrue 1% monthly interest thereafter.
-   Company had $38.1M liquidity as of Mar. 31, 2026 and is evaluating cash, financing or strategic alternatives and lender consents to facilitate payment.

Original SEC Filing: LIFECORE BIOMEDICAL, INC. \\DE\\ \[ LFCR \] - 8-K - Jul. 02, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [LFCR.US](https://longbridge.com/en/quote/LFCR.US.md)

## Related News & Research

- [LFCR: Revenue and profit declined, with liquidity sufficient but major preferred stock redemptions looming](https://longbridge.com/en/news/294961714.md)
- [LFCR: Q2 revenue fell 6.2% to $34.2M, but new business wins and guidance reaffirmed](https://longbridge.com/en/news/294961069.md)
- [Chimera declares Q3 2026 Series A preferred dividend of $0.5 a share](https://longbridge.com/en/news/294951609.md)
- [Lifecore Biomedical to report fiscal Q2 results, host webcast](https://longbridge.com/en/news/294254929.md)
- [VGP to host webcast on H1 2026 results](https://longbridge.com/en/news/295056101.md)